RenovoRx, Inc. - Common Stock (RNXT)

RenovoRx Q3 2025 earnings show a 35% revenue miss, causing a stock drop. The clinical-stage biopharma provided a 2026 growth outlook to offset cash burn.

RenovoRx (RNXT) Q3 2025 Earnings Call Transcript

RNXT stock results show that RenovoRx met analyst estimates for earnings per share the second quarter of 2024.

Several biotech stocks are showing renewed strength over the past week, with their Momentum scores soaring in Benzinga's Edge Stock Rankings.

As the regular session of the US market on Wednesday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.

The session on Friday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.

Let's have a look at what is happening on the US markets before the opening bell on Friday. Below you can find the top gainers and losers in today's pre-market session.

RenovoRx (NASDAQ:RNXT) Q2 2025 revenue beats estimates at $422K, shares rise 4.8%. RenovoCath adoption grows, Phase III trial progresses. Strong cash position supports operations.

The US market is yet to commence its session on Monday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.

Discover the top movers in Friday's pre-market session and stay informed about market dynamics.

Let's have a look at what is happening on the US markets after the closing bell on Thursday. Below you can find the top gainers and losers in today's after hours session.